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Abstract Viable donor skin is still considered the
goldstandardforthetemporarycoveringofburns.Since
1985, the Brussels military skin bank supplies cryopre-
served viable cadaveric skin for therapeutic use.
Unfortunately, viable skin can not be sterilised, which
increases the risk of disease transmission. On the other
hand, every effort should be made to ensure that the
largestpossiblepartofthedonatedskinisprocessedinto
high-performance grafts. Cryopreserved skin allografts
that fail bacterial or fungal screening are reworked into
‘sterile’ non-viable glycerolised skin allografts. The
transposition of the European Human Cell and Tissue
DirectivesintoBelgianLawhaspromptedustoinstalla
pragmatic microbiological screening and acceptance
procedure, which is based on 14 day enrichment broth
cultures of ﬁnished product samples and treats the
complex issues of ‘acceptable bioburden’ and ‘absence
of objectionable organisms’. In this paper we evaluate
this procedure applied on 148 skin donations. An
incubation time of 14 days allowed for the detection of
an additional 16.9% (25/148) of contaminated skin
compared to our classic 3 day incubation protocol and
consequently increased the share of non-viable glyc-
erolised skin with 8.4%. Importantly, 24% of these
slow-growing microorganisms were considered to be
potentiallypathogenic.Inaddition,weraisetheissueof
‘representative sampling’ of heterogeneously contam-
inated skin. In summary, we feel that our present
microbiological testing and acceptance procedure
assures adequate patient safety and skin availability.
The question remains, however, whether the supposed
increasedsafetyofourskingraftsoutweighsthereduced
overall clinical performance and the increase in work
load and costs.
Keywords Allograft donor skin  Cell and tissue
banking  Cryopreservation  Bacteriological and
fungal contamination  Screening
Introduction
Human allograft skin is most often obtained from
cadaveric donors and used to bring about a tempo-
rary—it will inevitably be rejected—wound closure
on full thickness burn or chronic wounds. It acts as a
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of water, protein, electrolytes and heat through the
wound and decreasing the risk of infection. It is also
known to decrease wound pain and the frequency of
dressing changes (Britton-Byrd et al. 2008).
Fresh viable cadaveric skin is considered the best
biologic dressing for burns because it provides a
faster and more durable adherence to the wound bed
and a better control of microbiological contamination
than preserved skin (Greenleaf et al. 1991; Cinamon
et al. 1993; Pianigiani et al. 2005). A major concern
with the use of fresh cadaveric skin is the risk of
disease transmission (Kearney 2005; Pianigiani et al.
2006). To enable a better availability and a more
extensive quality and safety control (ample time for
screening), skin allografts are often preserved in skin
banks. Human allograft skin can be preserved by
numerous methods: cool storage (2–8C), cryopres-
ervation (-20 to -196C), deep freezing, freeze
drying or dehydration using high-concentration sol-
utes like glycerol (Kearney 2005). These methods
amount to different ranges of allograft skin viability,
integrity, microbiological contamination and immu-
nogenicity (Ingham et al. 1993; Hettich et al. 1994;
Richters et al. 1997; van Baare et al. 1998; Bravo
et al. 2000; Saegeman et al. 2008). Glycerol pre-
served allograft skin, for example, is non-viable and
has been used successfully in burn surgery in the past
(Kreis et al. 1989; de Backere 1994; Huang et al.
2004). Cryopreservation is considered to be the best
method for the long-term preservation of skin (Kear-
ney 2005). Cryopreserved cadaveric skin exhibits a
certain level of viability and engrafts to the wound
bed, forming an excellent substrate for revasculari-
zation and recolonisation by host cells (Aggarwal
et al. 1985; Cinamon et al. 1993, Kearney 2005).
Unfortunately, cryopreservation also supports bacte-
rial and fungal survival, which can be problematic in
the case of skin allograft preservation. Pianigiani
et al. recently (2010) discovered that microbiological
contamination of donor skin is signiﬁcantly affected
by the type of processing (cryo- or glycerol preser-
vation), with highest levels of contamination found in
cryopreserved donor skin. In contrast to most
harvested donor tissues (e.g. musculoskeletal tissue
and heart valves), skin tissue is inherently colonised
by a substantial amount of commensal microorgan-
isms and thus non-sterile at the time of harvesting. As
superﬁcial decontamination of the donor sites before
harvesting, using antiseptics, is not indefectible,
freshly harvested donor skin is often collected in
an antibiotics containing transport medium (Kearney
2005).
Unfortunately, sterilisation techniques cannot be
applied for viable cryopreserved skin as they inacti-
vate the skin cells (Kearney 2005).
The microbiological evaluation of inherently non-
sterile human cryopreserved skin is much more
complex than for sterile products. It is therefore very
difﬁcult to promulgate functionally realistic and
ethically acceptable guidelines for the evaluation of
cryopreserved donor skin for bacteria and fungi and
for their acceptability for clinical use.
Ideally, the microbiological screening strategy
for cryopreserved skin allografts should ensure a
total absence of ‘relevant pathogens’ as well as the
absence of substantial bioburdens of inherent skin
commensals.
Historically, in Belgium as in many other coun-
tries, the microbiological contamination of human
skin allografts was mostly assessed using routine
clinical microbiology methods, and more speciﬁc
2–3 day skin cultures. In December 2008, the Euro-
pean Human Cell and Tissue Directives (2004/23/CE,
2006/17/CE and 2006/86/CE) were transposed to
Belgian Law. To be accredited, Belgian human cell-
and tissue banks have to comply with quality and
safety criteria deﬁned in Royal Decrees (September
28, 2009). In addition, the Belgian Superior Health
Council published (October 1, 2008) practical and
detailed quality and safety criteria for human allo-
grafts. According to these criteria, presence of
pathogens (Table 1) in ﬁnished product samples
results in a deﬁnite rejection of the donor tissue if
no validated sterilisation or decontamination method
is applied. Skin allografts can however be accepted
for clinical use, without decontamination, when the
bacteriological and mycological cultures only reveal
low bioburdens of inherent inhabitants of the resi-
dential skin ﬂora. While this bioburden can be
determined using elaborate and expensive quantita-
tive cultures, it is permitted to use a more pragmatic
approach based on adequate 14 day microbiological
cultures. If these cultures are negative and all other
quality and safety criteria are met, skin allografts
can be released for clinical use. If microbiological
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123growth is detected (increased turbidity) during the
ﬁrst 7 days of incubation, a relatively high bioburden
is suspected and the tissue must be rejected, sterilized
or decontaminated using a validated method. If
growth is detected after this period (i.e. days 8–14),
the growing microorganism(s) need(s) to be identi-
ﬁed. Identiﬁcation of micro-organisms considered to
be pathogenic (Table 1) again implies rejection,
sterilisation or decontamination. If a common (e.g.
exhibiting no particular antibiotic resistance or viru-
lence) member of the skin ﬂora is identiﬁed as sole
contaminant, and all other quality requirements are
met, the cryopreserved skin allografts can be released
as such.
If a cocktail of antibiotics was used during the
transport and/or conditioning process, those drugs
need to be neutralised or washed away before the
actual bacteriological and mycological screening
procedure is started.
Skin donations that do not meet the quality and
safety criteria have to be destroyed (traceable) unless
an explicit informed consent for research use was
obtained from the donor, his legal representative or a
medical ethical committee.
The Brussels military skin bank preferably pro-
cesses cadaveric skin into viable cryopreserved
allografts. Cryopreserved skin that does not meet
the microbiological acceptance criteria is reworked
by glycerol-decontamination (Verbeken et al. 2011).
As such, the bank provides cryopreserved as well as
glycerolised skin, whilst assuring an optimal use of
the scarce donor skin. In the summer of 2008 we
introduced a microbiological screening and accep-
tance procedure for cryopreserved skin allografts
based on 14 day cultures of ﬁnished product samples.
Since then 148 cadaveric skin donations were
processed. With the exception of the transport
medium, which was updated in the course of 2009,
all donations were processed in an identical way.
In this paper we present the results of a retrospec-
tive evaluation of our speciﬁc microbiological
screening and acceptance procedure.
Materials and methods
Skin procurement
Skin from 148 cadaveric donors was obtained under
aseptic conditions in an autopsy room or operation
theatre. Skin allografts and blood samples (serolog-
ical screening) were recovered within respectively 48
and 24 h after death. The donors were refrigerated
(2–8C) within 6 h after death. The donor sites, most
often the back and the legs, were shaven and
thoroughly scrubbed with 7.5% polyvidon–iodine
soap (Iso-Betadine Savon Germicide, Meda Pharma,
Belgium), rinsed with tap water and disinfected with
0.5% (w/v) chlorhexidine and 70% (v/v) isopropanol
solution (Hibitane Plus, Mo ¨lnlycke Health Care, UK).
Non donor sites were covered with sterile operative
ﬁelds. The donor sites were lubricated with sterile
liquid parafﬁn (Fagron, Belgium) and skin strips
(approximately 300 9 50 9 0.3 mm) were removed
using a battery operated dermatome (Aesculap,
Germany). The donor skin was collected in a sterile
recipient (Maco Biotech storage pot, MacoPharma,
Belgium) containing sterile transport medium and
transported, on crushed ice, to the skin bank. Two
transport media (TM) were used. The ﬁrst 57 skin
donations were transported in TM1 (PAA Laborato-
ries GmbH, Austria), which consisted of Penicillin
(100,000 units/l), Streptomycin (100,000 units/l) and
Amphotericin B (1.25 mg/l) in Medium for the
Culturing of Epithelial Cells (MCEC). The following
91 skin donations were transported in TM2, which
Table 1 Non-limiting list of microorganisms, which should
not be present in the skin allograft
Bacteria
Acinetobacter baumannii
Beta-hemolytic streptococci
Burkholderia cepacia
Clostridium perfringens
Clostridium tetani
Corynebacterium diphteriae
Enterobacteriaceae (coliforms)
Pseudomonas aeruginosa
Staphylococcus aureus
Fungi
Aspergilus spp.
Candida spp.
Mucor spp.
Penicillium spp.
Other yeasts and fungi
Mycobacteria (at risk donors)
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123was composed of 800 ml MCEC (Invitrogen Life
Technology, Belgium) supplemented with 200 ml of
Cambridge Antibiotic Solution (CAS, Inverclyde
Biologicals Ltd, UK). CAS consisted of Gentamicin
sulphate (4 g/l), Imipenem/cilastin Na (0.2 g/l), Poly-
myxin B sulphate (0.2 g/l), Vancomycin HCl (0.05 g/
l) and Nystatin (2,500,000 units/l) in Medium 199
with 25 mm HEPES.
Skin processing and sampling
Upon arrival in the skin bank, skin allografts were
kept in TM for min. 24 and max. 72 h at 2–8C prior
to further processing. Processing was performed
according to processing instructions and conform
with national regulations and guidelines, in a GMP
grade A laminar air ﬂow cabinet in a GMP grade C
environment. To wash away the antibiotics, skin
strips were incubated for 1 h at room temperature in
at least 0.2 ml/cm
2 of sterile 0.9% sodium chloride
solution (Vioser S. A., Greece).
Afterthewashingstep,arepresentativeskinsample
consisting of 20 randomly selected skin pieces of
approximately 2 cm
2 (1–2% of the skin donation),
wereobtainedasepticallyandtransferredtoarecipient
with 25 ml of thioglycollate broth with resazurin
(bioMe ´rieux,Belgium)andtoarecipientwith25 mlof
Sabouraud broth (bioMe ´rieux, Belgium) (10 skin
pieces per recipient) for in-process bacteriological
and mycological testing.
Skin strips were then trimmed and impregnated,
for 30 min, in sterile cryopreservation medium con-
sisting of 30% (v/v) glycerol (Pharma Belgium) in
Hartmann solution (Baxter, Belgium) and transferred
to sterile aluminum foil (Aluminum foil 8011A,
Alcomet AD, Bulgaria). Skin pieces were spread
(dermis side up) onto the foil and measured. An
inventory of all skin strips was made and recorded.
Each aluminum foil support held approximately
300 cm
2 of donor skin. After addition of an extra
5 ml of cryopreservation medium, each aluminum
foil support was folded and seal-packed in a sterile
laminated aluminum inner (CE class IIa Maco
BioTech Freezing Bag, MacoPharma, Belgium) and
outer (ATMI LifeSciences, Belgium) pouch. An extra
package containing a representative skin sample (see
above) for microbiological testing of the ﬁnished
product was made. The skin pouches were frozen
using a computerized biological freezer (Kryo Planer
MRV controller, Cryo Solutions, The Netherlands).
Cooling rates were -1C/min towards -6C, fol-
lowed by -5C/min towards -30C and -20C/min
towards -140C. Skin pouches were then transferred
to the vapour phase of liquid nitrogen (\-135C) for
long term storage. The microbiological test pouch
was thawed in a 37C water bath and the skin pieces
were rinsed in at least 1 ml/cm
2 of sterile 0.9%
sodium chloride solution (Vioser S. A., Greece) prior
to transfer to recipients with appropriate media (see
above) for bacteriological and mycological testing
(Fig. 1). ‘In-process’ and ‘ﬁnished product’ skin
samples were immediately sent to the clinical labo-
ratory of the Queen Astrid Military Hospital, which is
accredited for microbiological testing.
Microbiological cultures
In the clinical laboratory, skin samples were imme-
diately analysed for bacteriological and fungal con-
tamination using an extensive clinical microbiology
methodology (Fig. 2), designed to recover aerobic
and anaerobic as well as fast- and slow-growing
microorganisms. In short, the skin samples were
cultured for 14 days at appropriate temperatures and
examined daily for visual evidence of growth
(turbidity). Skin samples were not disrupted (e.g. by
stomaching or sonicating) as this caused the medium
to appear turbid, making the detection of microor-
ganism growth difﬁcult. We assumed that 14 days
was enough time for the bacteria to migrate from the
adnexal structures to the edges of the skin samples.
Fig. 1 Skin samples for bacteriological and mycological
testing
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observed, different agar plates (Manitol Salt, McCon-
key, Blood, Candida-ID2 and Sabouraud agar, bio-
Me ´rieux, Belgium) were inoculated and incubated at
appropriate temperatures (see Fig. 2). Plates for
anaerobes were incubated under anaerobic conditions
(Anaerogen compact, Oxoid, Belgium). Cultures
showing growth were identiﬁed to the genus and
species level using selective media (Candida-ID2
agar), automated biochemical tests (VITEK 2, API
ID32A or C, all from bioMe ´rieux, Belgium) or, in the
case of ﬁlamentous fungal colonies, microscopic
observation. Antibiotic susceptibility was also
assessed with the VITEK 2 system.
Acceptance procedure
The acceptance or eventual glycerol-decontamina-
tion or destruction of cryopreserved skin allografts
depends on the magnitude of bacterial load and the
presence or absence of pathogenic microorganisms,
factors which are derived from 14 day cultures of
ﬁnished product samples. This complex proce-
dure is graphically represented in a decision tree
(Fig. 3).
Results and discussion
In light of the chronic shortage of human skin for
burn wound treatment and out of respect for the
donor and his family, every effort should be made to
ensure that donated human skin does not go to waste.
In view of an optimal conservation of clinically
relevant properties of skin allografts, we strive to
provide the physicians with as much high quality
cryopreserved donor skin as possible. These choices
entail the complex issues of ‘acceptable bioburden’
and ‘absence of objectionable organisms’.
In 2008 we introduced a pragmatic microbiolog-
ical screening and acceptance procedure for cryopre-
served skin allografts based on 14 day cultures of the
ﬁnished product samples, i.e. pieces of skin allografts
that have undergone all stages of production, includ-
ing packaging, cryopreservation and labelling. This
procedure was analogous to common drug manufac-
turing practices and compliant with the relevant
national regulations, standards and guidelines. In this
paper we evaluate this procedure applied on 148 skin
donations. As could be expected, antibiotics were not
successful in a signiﬁcant part of the skin retrievals.
At 2–8C, TM1 failed to decontaminate no less than
47.4% (27/57) of skin donations and even the broad
Bacteria
Fungi and yeasts
Skin fragments (10 x 2 cm²)
in 25 ml thioglycollate broth 
Skin fragments (10 x 2 cm²)
in 25 ml Sabouraud broth 
Incubate 
at 37 °C
Gramm 
staining
Aerobic bacteria
(Growth on the surface)
Anaerobic bacteria
(Growth on the bottom)
Inoculate manitol salt, 
McConkey and blood agar,
incubate for 18-24 h at 37 °C
Inoculate blood agar and
incubate for 48 h at 37 °C
under anaerobic conditions
Identification/antibiogram 
of growing organisms 
(VITEK 2)
Identification of 
growing organisms 
(API ID32A)
Inoculate Candida-ID2
and Sabouraud agar and
incubate for 14 days at 25 °C
Incubate 
at 37 °C
Inoculate Candida-ID2
and Sabouraud agar and
incubate for 18-24 h at 25 °C
Identification of growing 
organisms (Candida ID2, API ID32C, 
VITEK 2 and microscopy)
After 24 h
After 14 days 
or upon growth 
within 7 days
After 14 days 
or upon growth 
within 7 days
Fig. 2 Overview of the clinical microbiology methodology for the testing of skin samples for bacteria, fungi and yeasts
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123spectrum antibiotic containing TM2 solution was not
capable of decontaminating 17/91 (18.7%) skin
batches (Table 2). Antibiograms revealed that these
bacteria were sensitive (in vitro) to at least one of the
antibiotics present in the CAS-cocktail. Rooney et al.
(2008) reported that approximately 22% of skin
allografts were not reliably decontaminated by anti-
biotic treatment. There are two likely causes as to
why antibiotic cocktails are not efﬁcient in some
cases. First of all, bacteria can be hidden deep into the
harvested skin (e.g. in the dept of the hair-follicles)
where the antibiotics can’t reach them in due time
and, secondly, the optimal operating temperature of
numerous antibiotics is much closer to 37C than to
2–8C (Kearney 2005). We are therefore currently
evaluating the inclusion of an additional short (to
limit cell inactivation) antibiotic incubation step at
37C.
Classical 3 day cultures allowed for the detection
of contamination in 12.8% (19/148) of skin retrievals
(Table 2; Fig. 4). Extension of the culture period to
14 days revealed contamination in an additional 25
(16.9%) skin donations, bringing the total to 44
(29.7%) (Table 2; Fig. 4).
As reported by other authors (Ireland and Spelman
2005; Neely et al. 2008; Pianigiani et al. 2010), the
most commonly isolated microorganisms were com-
mon skin contaminants like coagulase negative
staphylococci, especially Staphylococcus epidermidis
(35.4% of positive cultures), but occasionally coli-
forms like Eschericchia coli (6.3%) and Klebsiella
pneumoniae (6.3%) and recognised bacterial and
fungal pathogens like Candida albicans (10.4%),
Pseudomonas aeruginosa (4.1%) and Staphylococcus
aureus (4.1%) were isolated (Table 3). Forty-three
percent (19/44) of contaminations were revealed after
48 h cultures, while the remaining 56.8% (25/44) of
contaminations were only revealed after at least
3 days of incubation (Fig. 4). Britton-Byrd et al.
(2008) analysed 7 day cultures in 735 skin donations
and reported that only one had positive cultures post
3 days. They consequently concluded that 3 day
microbiologic cultures are as safe as 7 day cultures.
Glycerol-based 
recovery procedure 
(Verbeken et al. 2011)
Harvested donor skin
in transport medium 
(24-72 h at 2-8 °C)
Cryopreservation 
(<-135 °C)
in 30% glycerol
Skin processing
14-day culture of 
skin sample 
(finished product)
Growth
7-day
Yes
Growth
8-14-day
Yes Pathogen 
identified
Yes
Spore-form.
identified
No
Yes
No No
Skin released
Other 
quality req.
are met
Skin rejected
and destroyed
Yes
No
14-day culture of 
skin sample 
(in process control)
14-day culture of 
skin sample 
(finished product)
Growth
14-day
Other 
quality req.
are met
Yes
No
No
Yes
Fig. 3 Decision tree of the acceptance procedure for skin allografts
Table 2 Number of positive cultures in relation to transport
medium and culture period
Culture period
(days)
Number of donations with positive culture
(%)
TM1
(n = 57)
TM2
(n = 91)
Total
(n = 148)
B2 13 (22.8) 6 (6.6) 19 (12.8)
[2 B 7 5 (8.8) 4 (4.4) 9 (6.1)
[7 B 14 9 (15.8) 7 (7.7) 16 (10.8)
Total 27 (47.4) 17 (18.7) 44 (29.7)
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123Interestingly, we observed that 16 (64%) of these post
3 day culture positives only appeared post 8 days of
incubation. Most of the slow growers were skin
commensals, like propionibacteria, which are known
to be slow-growers. Not negligible, however, is the
fact that 24% (6/25) of these slow-growers were
considered to be potentially pathogenic (C. albicans,
P. aeruginosa. S. aureus, E. faecium and K. pneu-
moniae) (Fig. 4). In accordance with our acceptance
procedure (Fig. 3), these contaminated skin batches
were glycerol-decontaminated and it was thus not
possible to investigate the clinical relevance of these
post 3 day positive cultures.
In 27.3% (12/44) of culture positive skin procure-
ments an 8–14 day culture period revealed the
presence of only commensals (Fig. 3). Ten of those
were released in the form of cryopreserved allografts,
two were destroyed, one due to a positive serology,
another due to a belatedly discovered donor
malignancy.
The remaining 32 culture positive skin batches
were reworked using a validated glycerol-based
decontamination protocol (Verbeken et al. 2011)
and were again subjected to microbiological screen-
ing (Fig. 3). Twenty-nine were released in the form
of non-viable glycerolised skin, two were destroyed
after emergence of the endospore-forming bacterium
Bacillus subtilis during the decontamination proce-
dure, one was destroyed due to a non-conform blood
sample. It is plausible that B. subtilis remained
dormant or was overgrown by the other contaminat-
ing ﬂora in the initial microbiological screening, but
was respectively reactivated or selected by the
glycerolisation process. Note that using 3 day cul-
tures, as was the case until mid 2008, would have
given rise to the glycerol-decontamination of 19 skin
donations.
An additional issue that came up during our
evaluation was the one of ‘relevant sampling’. In
pharmaceutical product manufacturing it is assumed
that the distribution of microbiological contamination
is homogeneous throughout the product. This allows
for a ‘representative’ sample for microbiological
evaluation that represents a small part of the batch.
However, in practice, it is well-known that microbi-
ological contamination is never homogeneous and
certainly not when it comes to human donor skin,
which is not of uniform consistency, composition
and—most important in this context—bacterial load,
and can not be homogenized (e.g. by mixing). This
issue surfaced when reviewing the results of the in-
process microbiological tests. The 14 day cultures of
the skin sampled prior to the cryopreservation
procedure revealed an extra 14 (9.5%) contaminated
donations, including 8 with a pathogen listed in
Table 1. It is likely that at least a part of these
contaminating microorganisms survived cryopreser-
vation and consequently did not come to light during
the microbiological screening of the ﬁnished product.
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Fig. 4 Skin culture results in relation to the culture period
Table 3 Skin contaminants and their prevalence
Micro-organism Prevalence (Number
of donations)
Pathogens (see Table 1)2 0
Candida albicans 5
Escherichia coli 3
Klebsiella pneumoniae 3
Staphylococcus aureus 2
Pseudomonas aeruginosa 2
Enterococcus faecalis 2
Clostridium perfringens 1
Enterobacter cloacae 1
Enterococcus faecium 1
Non pathogens 28
Staphylococcus epidermidis 17
Staphylococcus capitis 5
Staphylococcus warneri 2
Corynebacterium minutissimum 1
Propionibacterium acnes 1
Staphylococcus coagulase negative 1
Staphylococcus simulans 1
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the batch does not allow for a watertight microbio-
logical screening of very unevenly contaminated skin
and consider revising our sampling procedure. The
clinical relevance of these contaminations, which
potentially eluded the microbiological screening
procedure, was investigated. No adverse reactions
were reported and a review of the medical ﬁles of the
18 acceptor patients showed no indications of a
possible transfer of microorganisms from the skin
grafts. For three patients the infecting species
matched those identiﬁed in the ‘in process’ samples,
but the infection and graft sites and dates did not
match. These ﬁndings correspond with the report of
Neely et al. (2008). They analysed the cultures of 61
skin donations and 38 acceptor patients and found
that none of microbes isolated from any burn patient
allograft site matched microorganisms from donor
allograft cultures.
Even so, we are considering the integration of
these in-process microbiological cultures in the
acceptance procedure of cryopreserved skin grafts
(dotted line in Fig. 3).
In summary, 70.3% (104/148) of skin donations
showed negative 14 day cultures and could be consid-
ered to be ‘sterile’, in analogy with sterility tests in
pharmaceuticals,whichalsorequire14 dayincubation.
An additional 6.8% (10/148) of skin donations exhib-
ited a low commensal bioburden and could be
considered to be ‘aseptic’ (free from pathogenic
microorganisms), which is at least compatible with
the microbiological qualiﬁcation of the setting where
most of the grafts will eventually end up, i.e. a non-
sterile (burn) wound in an aseptic environment (e.g. an
operating theatre). Obviously, this reasoning does not
apply for human tissues that are initially sterile (e.g.
musculoskeletaltissueandheartvalves)andaregrafted
inside the body. Successful glycerol-decontamination
resulted in the release of an extra 19.6% (29/148) of
skin donations in the form of glycerolised skin
allografts. These non-viable glycerolised skin allo-
grafts are used for some speciﬁc indications or when
cryopreservedviableskinisnotavailable.Finally,only
two (1.4%) skin donations failed the microbiological
acceptance criteria and were destroyed.
Although there are no clear indications that the use
of 14 day microbiologic cultures is safer than 3 day
cultures, when the culture results are used as the basis
of the acceptance procedure described in this paper
(Fig. 3), they did not give rise to an increase in
rejection rate, but they did effectuate an increase in
the percentage of donations that had to be released as
less effective non-viable glycerolised skin allografts
from 12.8% (19/148) to 21.6% (32/148). We feel that
our microbiological testing and acceptance procedure
assures patient safety and skin availability. The
question remains, however, whether the potentially
increased safety of our skin grafts outweighs the
reduced overall clinical performance and the increase
in work load and costs associated with the extended
processing and microbiological testing procedure.
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